Beclin-1, Bcl-2, and LC3-II were significantly downregulated, while LC3-I and p62 were significantly increased on the transcriptomic level in EMC patients compared to term controls (Figure 2B, panels a–e). The gene discussed is BCL2; the disease is extraskeletal myxoid chondrosarcoma.